|
KMID : 1161920200170020047
|
|
Journal of Medicine and Life Science
2020 Volume.17 No. 2 p.47 ~ p.52
|
|
|
The relationship between glucagon levels and cardiovascular risk in patients with type 2 diabetes
|
|
Jeong Woo-Seok
Moon Jae-Cheol
Yoo So-Yeon
|
|
|
Abstract
|
|
|
Background: Glucagon regulates glucose metabolism as well as fat metabolism and keton body production. The new antidiabetic drug, sodium-glucose co-transporter-2 inhibitors, that increase glucagon, reduced the risk of cardiovascular death and hospitalization for heart failure. Presence of metabolic syndrome is important risk factors for cardiovascular disease (CVD) in type 2 diabetes (T2DM) patients. We investigated the association of glucagon level with metabolic syndrome in patients with type 2 diabetes.
Method: This is a cross-sectional study involving 317 people with type 2 diabetes. Glucagon level were measured in a fasted state and 30 min after ingestion of a standard mixed meal. Metabolic syndrome was defined by criteria of the International Diabetes Federation
Result: Two hundred nineteen (69%) of the subjects have metabolic syndrome. The fasting glucagon level and postprandial glucagon level were no different between groups. The postprandial glucagon levels but not fasting glucagon levels increased significantly as the number of metabolic syndrome components increased. In hierarchical logistic regression analysis, the postprandial glucagon level have not been found to contribute significantly to metabolic syndrome even after adjusting for other covariates.
Conclusions: Taken together, fasting and postprandial glucagon levels are not associated with metabolic syndrome in patients with type 2 diabetes. However, further studies are needed to investigate the relationship between glucagon and cardiovascular risk in type 2 diabetes patients.
|
|
|
KEYWORD
|
|
|
Glucagon, Type 2 diabetes, Metabolic syndrome, Cardiovsacular risk
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|